Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Jan 27

PMID 33499047

Citations 21

Authors

Ralph El Hallal

Nana Lyu

Yuling Wang

Affiliations

Soon will be listed here.

Abstract

Epidermal growth factor receptor (EGFR) is estimated to be overexpressed in 60~80% of colorectal cancer (CRC), which is associated with a poor prognosis. Anti-EGFR targeted monoclonal antibodies (cetuximab and panitumumab) have played an important role in the treatment of metastatic CRC. However, the therapeutic response of anti-EGFR monoclonal antibodies is limited due to multiple resistance mechanisms. With the discovery of new functions for gold nanoparticles (AuNPs), we hypothesize that cetuximab-conjugated AuNPs (cetuximab-AuNPs) will not only improve the cytotoxicity for cancer cells, but also introduce expression change of the related biomarkers on cancer cell surface. In this contribution, we investigated the size-dependent cytotoxicity of cetuximab-AuNPs to CRC cell line (HT-29), while also monitored the expression of cell surface biomarkers in response to treatment with cetuximab and cetuximab-AuNPs. AuNPs with the size of 60 nm showed the highest impact for cell cytotoxicity, which was tested by cell counting kit-8 (CCK-8) assay. Three cell surface biomarkers including epithelial cell adhesion molecule (EpCAM), melanoma cell adhesion molecule (MCAM), and human epidermal growth factor receptor-3 (HER-3) were found to be expressed at higher heterogeneity when cetuximab was conjugated to AuNPs. Both surface-enhanced Raman scattering/spectroscopy (SERS) and flow cytometry demonstrated the correlation of cell surface biomarkers in response to the drug treatment. We thus believe this study provides powerful potential for drug-conjugated AuNPs to enhance cancer prognosis and therapy.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.

Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.

Spada A, Gerber-Lemaire S Nanomaterials (Basel). 2025; 15(3).

PMID: 39940134 PMC: 11820047. DOI: 10.3390/nano15030158.

EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy.

Djermane R, Nieto C, Vega M, Del Valle E Sci Rep. 2024; 14(1):29265.

PMID: 39587206 PMC: 11589782. DOI: 10.1038/s41598-024-80879-0.

Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy.

Kumar M, Goswami P, Jha A, Manjit M, Satpute A, Koch B Sci Rep. 2024; 14(1):29114.

PMID: 39582089 PMC: 11586409. DOI: 10.1038/s41598-024-80283-8.

Impact of metallic nanoparticles on gut microbiota modulation in colorectal cancer: A review.

Kumar A, Pramanik J, Batta K, Bamal P, Gaur M, Rustagi S Cancer Innov. 2024; 3(6):e150.

PMID: 39398260 PMC: 11467490. DOI: 10.1002/cai2.150.

References

Bishop K, Wilmer C, Soh S, Grzybowski B . Nanoscale forces and their uses in self-assembly. Small. 2009; 5(14):1600-30. DOI: 10.1002/smll.200900358. View

Leve F, Bonfim D, Fontes G, Morgado-Diaz J . Gold nanoparticles regulate tight junctions and improve cetuximab effect in colon cancer cells. Nanomedicine (Lond). 2019; 14(12):1565-1578. DOI: 10.2217/nnm-2019-0023. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

Ledel F, Stenstedt K, Hallstrom M, Ragnhammar P, Edler D . HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver. Acta Oncol. 2015; 54(4):480-6. DOI: 10.3109/0284186X.2014.983654. View

Liu D, Du L, Chen D, Ye Z, Duan H, Tu T . Reduced CD146 expression promotes tumorigenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling. Oncotarget. 2016; 7(26):40704-40718. PMC: 5130037. DOI: 10.18632/oncotarget.9930. View

Leto S, Trusolino L . Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl). 2014; 92(7):709-22. PMC: 4055851. DOI: 10.1007/s00109-014-1161-2. View

Tan C, Du X . KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol. 2012; 18(37):5171-80. PMC: 3468848. DOI: 10.3748/wjg.v18.i37.5171. View

Eaton P, Quaresma P, Soares C, Neves C, de Almeida M, Pereira E . A direct comparison of experimental methods to measure dimensions of synthetic nanoparticles. Ultramicroscopy. 2017; 182:179-190. DOI: 10.1016/j.ultramic.2017.07.001. View

Wang J, Koo K, Wang Y, Trau M . Engineering State-of-the-Art Plasmonic Nanomaterials for SERS-Based Clinical Liquid Biopsy Applications. Adv Sci (Weinh). 2019; 6(23):1900730. PMC: 6891916. DOI: 10.1002/advs.201900730. View

10.

Liu D, Sun J, Zhu J, Zhou H, Zhang X, Zhang Y . Expression and clinical significance of colorectal cancer stem cell marker EpCAM/CD44 in colorectal cancer. Oncol Lett. 2014; 7(5):1544-1548. PMC: 3997707. DOI: 10.3892/ol.2014.1907. View

11.

Liu X, Chen Y, Li H, Huang N, Jin Q, Ren K . Enhanced retention and cellular uptake of nanoparticles in tumors by controlling their aggregation behavior. ACS Nano. 2013; 7(7):6244-57. DOI: 10.1021/nn402201w. View

12.

Foroozandeh P, Abdul Aziz A . Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles. Nanoscale Res Lett. 2018; 13(1):339. PMC: 6202307. DOI: 10.1186/s11671-018-2728-6. View

13.

Ranjan Patra C, Bhattacharya R, Mukhopadhyay D, Mukherjee P . Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Deliv Rev. 2009; 62(3):346-61. PMC: 2827658. DOI: 10.1016/j.addr.2009.11.007. View

14.

Mackey M, El-Sayed M . Chemosensitization of cancer cells via gold nanoparticle-induced cell cycle regulation. Photochem Photobiol. 2013; 90(2):306-12. PMC: 4706148. DOI: 10.1111/php.12226. View

15.

Haraldsdottir S, Bekaii-Saab T . Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2013; 4(3):285-98. PMC: 3712294. DOI: 10.3978/j.issn.2078-6891.2013.028. View

16.

Bertotti A, Sassi F . Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clin Cancer Res. 2015; 21(15):3377-83. DOI: 10.1158/1078-0432.CCR-14-0848. View

17.

Groysbeck N, Stoessel A, Donzeau M, Cruz Da Silva E, Lehmann M, Strub J . Synthesis and biological evaluation of 2.4 nm thiolate-protected gold nanoparticles conjugated to Cetuximab for targeting glioblastoma cancer cells via the EGFR. Nanotechnology. 2019; 30(18):184005. DOI: 10.1088/1361-6528/aaff0a. View

18.

Nie , Emory . Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering. Science. 1997; 275(5303):1102-6. DOI: 10.1126/science.275.5303.1102. View

19.

Wang Y, Schlucker S . Rational design and synthesis of SERS labels. Analyst. 2013; 138(8):2224-38. DOI: 10.1039/c3an36866a. View

20.

Ahmed D, Eide P, Eilertsen I, Danielsen S, Eknaes M, Hektoen M . Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2013; 2:e71. PMC: 3816225. DOI: 10.1038/oncsis.2013.35. View